Regulatory Approvals Advance D-PLEX₁₀₀ in US and EU
2 reports, 2 independent
Updated Wed 00:00
No new developments lately
- Reports
- 2
- Developments
- 1
- Repetition
- 50%
New informationRepeats or wire copies
AI-generated briefing. Brind wrote this from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
The European Medicines Agency validated a Marketing Authorization Application for D-PLEX₁₀₀, granting single authorization across EU states. Separately, the product received Priority Review from the FDA. This regulatory progress follows PolyPid regaining full European commercialization rights to the product from ADVANZ PHARMA.
From investegate.co.uk
Why it matters
The regulatory validation by the European Medicines Agency and the FDA Priority Review advance the commercial viability of D-PLEX₁₀₀ in major global markets. These approvals confirm the product's potential market access and sales opportunities.
From investegate.co.uk
Who's involved
- FDARegulatory agency reviewing the product in the United States.
- European Medicines AgencyRegulatory authority that validated the product application across the European Union.
Keep exploring
The entities involved
- FDA
-
European Medicines Agency
highest regulatory authority on medicines in the European Union
Related events
- Allarity Therapeutics has established a facility in Horsholm, Northern Europe, and the FDA requires CLIA certification for biomarker testing.
- FDA approved combination clearances for Elanco's Experior use on June 27, 2025.
- Menarini Group and NewAmsterdam Pharma Company N.V. are collaborating on drug development, seeking marketing authorization in Europe through the EMA and EC process.
- FDA approval is the goal for product candidates from Daré Bioscience, Inc.
- Steriwave requires FDA approval for US market.